Goldman Sachs backs CRO Aragen, which it believes is well placed to gain from the “secular trend” of an outsourcing uptick by biopharma. Aragen has a string of alliances and is also assisting with both vaccine and test kit development against SARS-CoV-2 for its customers.

Dipharma appoints a new CEO, Xellia gets a new commercial head in North America, promotions are made at Lek, GVK Bio and the APhA, while appointments are seen at Auris Medical and Tris Pharma.

Takeda tantalizingly disclosed during its third quarter results that it has set aside funds for an acquisition worth around $450m in an undisclosed emerging market. What are the likely targets?

Micro Therapeutic Research Labs is now under the scanner over alleged data integrity concerns. European Medicines Agency (EMA) is evaluating medicines based on studies done by the Indian firm.